{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:06:57Z","timestamp":1792840017757,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jhepr.2024.101276","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T14:39:17Z","timestamp":1731767957000},"page":"101276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issah","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Racila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101276_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101276_bib2","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2024.101276_bib3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","article-title":"The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States","volume":"13","author":"Younossi","year":"2023","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes","volume":"4","author":"Younossi","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2024.101276_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cld.2023.01.007","article-title":"Economic burden and patient-reported outcomes of nonalcoholic fatty liver disease","volume":"27","author":"Stepanova","year":"2023","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2024.101276_bib7","first-page":"6216","article-title":"Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective","volume":"12","author":"Eskridge","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhepr.2024.101276_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12955-016-0420-z","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)","volume":"14","author":"Golabi","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jhepr.2024.101276_bib9","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","article-title":"Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib10","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib11","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","article-title":"Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001084","article-title":"Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis","author":"Younossi","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101276_bib13","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/hep4.1765","article-title":"Poor awareness of liver disease among adults with NAFLD in the United States","volume":"5","author":"Alqahtani","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2024.101276_bib14","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2024.101276_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jhep.2023.11.004","article-title":"Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib16","article-title":"The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease","volume":"6","author":"Younossi","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2024.101276_bib17","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib19","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.cgh.2021.11.004","article-title":"Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the Global Non-Alcoholic Steatohepatitis (NASH)\/Non-Alcoholic Fatty Liver Disease (NAFLD) Registry","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101276_bib20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/liv.13391","article-title":"A\u00a0disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD","volume":"37","author":"Younossi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2024.101276_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101276_bib22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jval.2016.02.005","article-title":"Performance and validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C","volume":"19","author":"Younossi","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jhepr.2024.101276_bib23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/jvh.13451","article-title":"Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV","volume":"28","author":"Younossi","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhepr.2024.101276_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000049","article-title":"Development and validation of a primary sclerosing cholangitis-specific health-related quality of life instrument: CLDQ-PSC","volume":"7","author":"Younossi","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2024.101276_bib25","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000709","article-title":"Development of a primary biliary cholangitis-specific version of Chronic Liver Disease Questionnaire: CLDQ-PBC","volume":"15","author":"Younossi","year":"2024","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101276_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apt.17346","article-title":"A\u00a0practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis","volume":"57","author":"Younossi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2024.101276_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.jhepr.2024.101276_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpsychores.2012.10.011","article-title":"Measurement of fatigue in cancer, stroke, and HIV using the functional assessment of chronic Illness Therapy - fatigue (FACIT-F) scale","volume":"74","author":"Butt","year":"2013","journal-title":"J\u00a0Psychosom Res"},{"key":"10.1016\/j.jhepr.2024.101276_bib29","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2024.101276_bib30","article-title":"The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes","volume":"4","author":"Younossi","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2024.101276_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apt.17301","article-title":"Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study","volume":"57","author":"Yilmaz","year":"2023","journal-title":"Aliment Pharmacol Ther"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:28:43Z","timestamp":1741652923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924002805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2589555924002805"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101276","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101276"}}